Ensysce Biosciences (ENSC) Stock: Buy, Sell, or Hold?
ENSC - Ensysce Biosciences, Inc. Common Stock
$0.40
-0.02 (-3.85%)
âŧ
5d:
-0.07%
30d:
+3.01%
90d:
+40.77%
WAIT
LOW Confidence
Analysis Updated: Oct 1, 2026 12:00 AM ET
Earnings: Nov 13, 2026
Get Alerted When ENSC Hits Your Target Price
Join 10,000+ traders who never miss a move
You're in! Check your email to confirm and set your target price.
100% Free
No spam, ever
Unsubscribe anytime
Interactive Price Chart (1 Month)
Loading chart...
Loading historical data...
Bottom Line:
âšī¸ NEUTRAL: ENSC is fairly priced but lacks strong directional signals. Wait for clearer setup or better entry on dips.
âšī¸ NEUTRAL: ENSC is fairly priced but lacks strong directional signals. Wait for clearer setup or better entry on dips.
In-depth Analysis How we analyze
Valuation Analysis: ENSC is currently trading at $0.40, which is considered slightly low relative to its 30-day fair value range of $0.40 to $0.47.
Technical Outlook: Technically, ENSC is in a strong uptrend. The price is currently testing key support at $0.40. A bounce from this level would confirm strength, while a break below could signal further downside. Short-term momentum is weak, with the stock down 3.8% recently.
Market Sentiment: The stock scores a mixed 52/100 on our bottoming-setup gauge, with only partial signs of a stabilized entry point. Wall Street analysts see significant upside, with an average price target of $8.25 (+1963.5%). Current signals suggest waiting for a better entry point before initiating new positions.
Technical Outlook: Technically, ENSC is in a strong uptrend. The price is currently testing key support at $0.40. A bounce from this level would confirm strength, while a break below could signal further downside. Short-term momentum is weak, with the stock down 3.8% recently.
Market Sentiment: The stock scores a mixed 52/100 on our bottoming-setup gauge, with only partial signs of a stabilized entry point. Wall Street analysts see significant upside, with an average price target of $8.25 (+1963.5%). Current signals suggest waiting for a better entry point before initiating new positions.
Quick Decision Summary
Current Position
SLIGHTLY LOW
Historical Trading Range
$0.40 -
$0.47
Company Quality Score
53/100
(HOLD)
Volume Confirmation
HIGH
Confidence Score
77.4%
All Signals
- BULLISH: Price oversold vs 30-day range
- NEUTRAL: Mixed technical signals (52/100)
- BULLISH: High volume confirmation
- BEARISH: Downward momentum (-3.8%)
- BULLISH: Trading 1963.5% below Wall St target ($8.25)
- WARNING: Composite score 53/100 in the bottom quintile â this cohort historically lags the market
Trading Range Analysis
30-Day Trading Range
$0.40 -
$0.47
Current vs Trading Range
SLIGHTLY LOW
Support & Resistance Levels
Support Level
$0.40
Resistance Level
$0.46
Current Trend
Strong Uptrend
Technical data as of
Oct 1, 2026
Fundamental Context
Forward P/E (Next Year Est.)
-8.00
Wall Street Target
$8.25
(+1963.5%)
Revenue Growth (YoY)
-15.1%
Profit Margin
-280.5%
Share & Embed Analysis
Last updated: October 02, 2026 1:27 AM ET
Data refreshes hourly during market hours. Next update: 2:27 AM
Data refreshes hourly during market hours. Next update: 2:27 AM
đĨ Top Stocks Breaking Out Now
| Ticker | Score | Recommendation | Change % |
|---|
Technical Signals Check
Is ENSC showing a specific setup today?
Insider Activity (6 Months)
0
Buys
0
Sells
0
Net
NEUTRAL
Top Rated Biotechnology Stocks
Top-rated stocks in Biotechnology by analyst ratings.
| Stock | Analyst Consensus | Analyst Target | Tradestie Score |
|---|---|---|---|
|
INSM
Insmed Inc |
STRONG BUY
21 analysts |
$199 | 58 HOLD |
|
RARE
Ultragenyx |
STRONG BUY
20 analysts |
$28 | 63 BUY |
|
CRSP
Crispr Therapeutics AG |
BUY
28 analysts |
$88 | 55 HOLD |
|
CYTK
Cytokinetics Inc |
STRONG BUY
21 analysts |
$110 | 58 HOLD |
|
RCKT
Rocket Pharmaceuticals IâĻ |
STRONG BUY
18 analysts |
$9 | 60 HOLD |
